Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients

Inhibrx Inc INBX announced that the FDA lifted the partial clinical hold on studies evaluating its death-receptor 5 (DR5) agonist, INBRX-109. Patient enrollment is expected to resume next month.
In March 2023, the company paused patient enrollment for the INBRX-109 (DR5 agonist) trials due to the pre-defined stopping rules built into the Phase 2 protocol.
With data from over 200 patients dosed with INBRX-109, the company could identify elderly individuals with fatty liver disease at risk for severe liver toxicity.
Phase 1 combination cohorts are expected to begin reading out by the end of 2023. Data from the registration-enabling trial in unresectable or metastatic conventional chondrosarcoma is expected during 2H 2024.
The company also initiated a registration-enabling trial for INBRX-101, an optimized recombinant human AAT-Fc fusion protein emphysema due to alpha-1 antitrypsin deficiency (AATD).
The trial's primary endpoint is the mean change in the average functional AAT (fAAT) concentration from baseline.
The initial read-out from the ElevAATe trial is expected to occur in late 2024.
Price Action: INBX shares are down 0.50% at $19.88 on the last check Wednesday.